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Circulating level of a2-macroglobulin–b2-microglobulin com-
plex in hemodialysis patients.
Background. The presence of a2-macroglobulin (a2M) in
amyloid tissue from patients with dialysis-related amyloidosis
(DRA) was demonstrated by Argile´s et al in 1989. Thereafter,
the formation of the complex of b2-microglobulin (b2m) with
a2m was confirmed directly by in vitro study. In Alzheimer’s
disease, complex formation of amyloid b-peptide and a2M is
considered to play an important role in the pathogenesis by
modifying the degradation processes of amyloid protein. Thus,
we hypothesized that the a2M-b2m complex is an important
factor in the pathogenesis of DRA as well. Here, we measured
the circulating levels of a2M-b2m complex in the maintenance
hemodialysis patients and discussed about its clinical signifi-
cance in DRA.
Methods. One hundred and thirty-seven hemodialysis pa-
tients and 11 prehemodialysis chronic renal failure (CRF)
patients were included in this study. The affinity of purified a2M
for b2m was confirmed by a highly sensitive 27 MHz quartz crys-
tal microbalance (QCM). The presence of circulating a2M-b2m
complex was analyzed by immunoblotting analysis. Further-
more, the serum levels of a2M-b2m complex were measured
by sandwich enzyme immunoassay.
Results. QCM analysis revealed the high affinity of a2M for
b2m. The presence of circulating a2M-b2m complex was de-
tected in two out of a total 11 prehemodialysis CRF patients
and in 95 out of the total of 137 hemodialysis patients. None of
the healthy subjects, however, were observed to present with
any a2M-b2m complex. Serum levels of the a2M-b2m complex
were correlated to the duration of hemodialysis (P = 0.043).
Serum levels of the a2M-b2m complex were significantly higher
in patients with high DRA score than in patients with negative
DRA score (P =0.018). Moreover, serum levels of the a2M-b2m
complex showed significantly lower in the hemodiafiltration pa-
tients compared to the hemodialysis patients (P = 0.002) and
showed a strong correlation with DRA score in hemodialysis
patients excluding 11 hemodiafiltration patients (P = 0.0004).
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Conclusion. This study is the first to demonstrate the pres-
ence of circulating a2M-b2m complex in hemodialysis patients.
Furthermore, we observed the correlation between serum lev-
els of a2M-b2m complex and clinical characteristics of DRA.
Thus we concluded that a formation of an a2M-b2m complex
may be implicated in DRA.
a2-macroglobulin (a2M) is a major protease inhibitor
in vivo [1, 2]. So far, several reports have been pub-
lished suggesting the presence of protease inhibitors
such as a2M and a1 antichymotripsin in amyloid fibrils
from Alzheimer’s disease or dialysis-related amyloidosis
(DRA) patients [3–6]. More recently, the very potent in-
hibitory action of a2M on proteases has been interpreted
as being indicative of an involvement of a2M in amyloid-
related protein metabolism. In consequence of this, it has
been hypothesized that a2M may modify the degradation
processes of amyloid proteins and may play an active role
in the pathogenesis of amyloidosis.
In Alzheimer’s disease, amyloid b peptide, a precursor
protein of the disease, has now been corroborated to form
a complex with a2M in in vitro studies [7, 8].
Subsequently, b2-microglobulin (b2m), a precursor
protein of DRA, has been reported to form a complex
with a2M [9]. On the basis of this evidence, the “a2M hy-
pothesis” has been forwarded by Argile´s et al [10] as an
interesting mechanism to account for the pathogenesis of
DRA. Based on this complex-mediated promotion con-
cept, we established an assay system using the enzyme
immunoassay method for a2M-b2m complex and mea-
sured its serum level in 137 hemodialysis patients as well
as 11 prehemodialysis patients.
METHODS
Subjects
One hundred and thirty-seven hemodialysis patients,
11 prehemodialysis patients with chronic renal failure
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(CRF) (control subjects, prehemodialysis CRF patients),
and 15 normal persons were enrolled in this study after
obtaining their oral consent.
All patients were nondiabetic. Their average ages were
58 years in the hemodialysis patients, 61 years in the con-
trol subjects, and 33 years in the normal persons. Gender
breakdown was 77 males and 60 females of the hemodial-
ysis patients, nine males and two females of the prehe-
modialysis CRF patients, and 12 males and three females
of normal persons. Duration of hemodialysis varied from
2 to 290 months, 123 months in average. All hemodialy-
sis patients underwent hemodialysis or hemodiafiltration
with bicarbonate dialysate twice or three times a week.
Several kinds of dialyzers were used at the time of the
study, including polysulfone (N = 45), polyacrylonitrile
(N = 36), ethylenevinylalcohol (N = 31), cellulose triac-
etate (N = 20), and others (N = 5).
The clinical diagnosis of DRA was evaluated as previ-
ously reported [11]. In brief, all clinical signs were scored
by the criteria of Gejyo et al [12], which ranks the clini-
cal features of DRA from 0 to 7 according to joint pain,
bone cyst on x-ray film, and carpal tunnel syndrome. The
DRA scores were negative in 84 cases (0 in 58 cases, 1 in
26 cases), mild in 33 cases (2 in 21 cases, 3 in 12 cases),
and high in 20 cases (4 in ten cases, 5 in five cases, 6 in
three cases, and 7 in two cases).
The operation for carpal tunnel syndrome had been
done in 20 patients, the amyloid bone cyst in either carpal,
shoulder, or hip bone was confirmed in 70 patients and 47
patients showed symptoms of multiple joint pain. Eleven
patients who had a moderate or high DRA score had been
undergoing hemodiafiltration for 6 months or more.
As far as we could survey, there were no reports con-
cerning the complex of a2M-b2m even in the patients with
the systemic AA amyloidosis. Therefore, age-matched
prehemodialysis CRF patients served as control in this
study.
Laboratory characteristics
Serum creatinine values were 12.0 ± 0.3 mg/dL in the
hemodialysis patients and 5.4 ± 2.3 mg/dL in the pre-
hemodialysis CRF patients. Serum values of b2m were
35.7 ± 8.5 mg/L in the hemodialysis patients and 10.7 ±
6.0 mg/L in the prehemodialysis CRF patients. Values
of serum total protein, albumin, C-reactive protein, and
concentration of hemoglobin were 6.5 ± 0.4 g/dL, 3.8 ±
0.3 g/dL, 0.24 ± 0.31 mg/dL, and 10.0 ± 1.2 g/dL, respec-
tively, in hemodialysis patients. All data in hemodialysis
patients were values before hemodialysis.
Measurement of a circulating a2M-b2m complex
The affinity of b2m for a2M. The affinity of b2m for
a2M was examined by using a highly sensitive 27 MHz
quartz crystal microbalance (QCM) (Affinix Q) (Inishi-
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Fig. 1. Western blotting of the a2-macroglobulin (a2M)-b2-micro-
globulin (b2m) complex in vitro. Commercial a2M, commercial b2m
and a2M-b2m complex were submitted to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and blotted with anti-
b2m polyclonal antibody (A) or anti-a2M polyclonal antibody (B).
amu Co., Tokyo, Japan) as described earlier [13, 14].
Briefly, 2 lL of 200 lg/mL a2M was directly immobilized
on a QCM plate, and the plate was soaked in 6 mL of 10%
dimethyl sulfoxide (DMSO) at 25◦C. The resonance fre-
quency of the QCM was defined as the 0 position after
equilibrium. The stability and drift of the 27 MHz QCM
frequency in the solution were ± 5 Hz for 12 hours at
25◦C.
Preparation of standard a2M-b2m complex. A a2M-
b2m complex was prepared as described previously [9].
Other chemicals were of analytic grade. In outline, 1 mL
of 0.1 mg/mL b2m (Sigma Chemical Co., St. Louis, MO,
USA) was incubated with 1 mL of 1 mg/mL a2M (Sigma
Chemical Co.) for 36 hours in 66.6 mmol/L phosphate
buffer at room temperature. Specificity of the standard
complex was studied by Western blotting as shown in
Figure 1. The complex was used as a sample for Western
blotting or a standard for enzyme immunoassay.
Western blotting. Prepared a2M-b2m complex, com-
mercial b2m, and commercial a2M were run by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) at 18 mA for 11/2 hours with a 4% to
20% gradient gel (Tefco, Tokyo, Japan). Prepared a2M-
b2m complex was pretreated at 100◦C for 5 minutes by
mixing with 2-mercaptethanol of 5% final concentration.
After transfer to a polyvinylidene difluoride (PVDF)
membrane (Millipore, Bedford, MA, USA) for 1 hour
at 20 V, the membrane was incubated with Block Ace
(Dainippon Pharmaceutical, Osaka, Japan) for 1 hour
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followed by three washes with 20 mmol/L phosphate-
buffered saline (PBS) (pH 7.4) containing 0.05% Tween
20 (washing buffer). The membrane was then incubated
with biotin-labeled anti-a2M antibody or anti-b2m an-
tibody at room temperature for 1 hour. After the reac-
tion, the membrane was washed three times with wash
buffer and soaked by shaking in 5 mL of PBS contain-
ing an avidin-peroxidase-labeled biotin complex (Vectas-
tain ABC Kit) (Vector, Burlingame, CA, USA) at room
temperature for 30 minutes. Thereafter, the membrane
was washed three times repeatedly with the wash buffer
and reacted with nitrotetrazolium blue solution contain-
ing 0.02% hydrogen peroxide and the reduced form of
nicotinamide adenine dinucleotide (NADH).
Biotin labeling of anti-a2M antibody. Biotinylation of
anti-a2M polyclonal antibody (Rockland) (Gilbertsvilles,
PA, USA) was performed using sulfosuccinimidyl D-
biotin (Biotin Sulfo-OSu) (Dojindo, Kumamoto, Japan).
First, 1 mL of the antibody solution (0.7 mg/mL) in
0.01 mol/L hepes buffer (pH 8.5) was prepared. Next,
0.1 mL of 1 mmol/L Biotin Sulfo-OSu in distilled wa-
ter was prepared and then added to the antibody solu-
tion. After complete mixing, the solution was incubated
at room temperature for 4 hours. The biotinylated anti-
body solution was loaded into the desalting column (R1).
A coupling anti-b2m antibody to horseradish peroxi-
dase. Five milligrams of horseradish peroxidase (HRP)
(Toyobo, Osaka, Japan) was suspended in 1.2 mL of wa-
ter and added to 0.3 mL of a freshly prepared 0.1 mol/L
sodium periodate solution in 10 mmol/L sodium phos-
phate (pH 7.0). After the HRP solution had been
incubated at room temperature for 20 minutes, it was
dialyzed versus 1 mmol/L sodium acetate (pH 4.0) at 4◦C
with several changes overnight. The HRP solution was
removed from the dialysis tube, added to 0.5 mL of anti-
b2m antibody solution, then prepared to 10 mg/mL in
20 mmol/L carbonate buffer (pH 9.0). Next, the HRP
antibody solution was incubated at room temperature
for 2 hours. After adding 0.1 mL of sodium borohy-
dride (4 mg/mL in water) (Wako, Osaka, Japan) to
the HRP antibody, the solution was incubated at 4◦C
for 2 hours. The HRP antibody solution was then di-
alyzed by several changes of 10 mmol/L sodium PBS
(pH 7.4).
Two-step sandwich enzyme immunoassay. Measure-
ment of the a2M-b2m complex in serum was performed
by two-step sandwich enzyme immunoassay (two-step
EIA) using full automatic analysis equipment MI01 (A &
T, Kanagawa, Japan). A principle of assay followed two
steps: (1) a2M in serum was captured on reaction cup
by biotin labeled anti-a2M antibody through antibiotin
antibody, (2) b2m of the complex was detected by HRP-
labeled anti-b2m antibody. In the first step, the reaction
cup used for immobilizing antibiotin polyclonal antibody
was coated with antibiotin polyclonal antibody (Nippon
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Fig. 2. A reference line of two-step enzyme imuunoassay. Abbre-
viations are: a2M-b2m complex, a2-macroglobulin-b2-microglobulin
complex; K/S, change for 1 minute of a ratio of the Kubelka-Munk
coefficients; K is absorption and S is scattering.
Chemiphar, Tokyo, Japan) at 2.5 lg/cup prior to mea-
surement. Twenty microliters of biotin-labeled anti-a2M
antibody solution (R1), containing 1% bovine serum al-
bumin (BSA), 1% mouse serum, and 0.03% Microcide
I (Amresco, Solon, OH, USA) in 20 mmol/L PBS, and
50 lL of the sample were mixed and preincubated for
5 minutes at 45◦C in tube. Then, 50 lL of the R1 sample
mixture was transferred to the reaction cup. Twenty mi-
croliters of HRP-coupled anti-b2m antibody (R2), con-
taining 1% BSA, 1% mouse serum, and 0.03% Microcide
I (Amresco) in 20 mmol/L PBS, was added to the reac-
tion cup (second step). The reaction cup contents were
then incubated for 2 minutes at 45◦C and washed two
times with 0.05% Tween 20 solution. After the addition
of 30 lL of chromogen (A & T) which consists of 3,3′,5,5′-
tetramethylbenzidine and hydrogen peroxide, changes of
laser reflectance were measured.
The a2M-b2m complex, prepared in vitro, was used
as the standard for the changes of laser reflectance. The
sera of normal persons, hemodialysis, and prehemodialy-
sis CRF patients were used as samples. The complex con-
centration of the samples was calculated with an MI01 (A
& T) by fitting the standard curve using a spline function.
The reference line showed a good linearity from 0 to 1.0
U/mL (Fig. 2). The intra-assay coefficient of variation was
4.67%.
Statistical analysis
Results are expressed as mean ± SD. Statistical anal-
ysis was performed using the software package, Stat
View version 5.0 for Windows. Differences between the
groups were compared using the Mann-Whitney U test
for nonnormally distributed variables, and for normally
distributed variables, compared using unpaired t test. To
evaluate the relation between variables, Pearson’s cor-
relation coefficient in normally distribution, and Spear-
man’s ranked correlation coefficient in nonnormally
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Fig. 3. Affinity of a2-macroglobulin (a2M) for b2-microglobulin (b2m)
by quartz crystal microbalance (QCM). (A) Frequency changes (F) of
the QCM directory immobilized with b2m responding to the addition
of a2M as described in the text (Ka 443.27 nmol/L, Fmax 232.93 Hz,
and Fmax 232.93 (Hz). (B) The Eadie-Hofstee plots (y = −443.27x +
232.93).
distribution were used. A P value less than 0.05 were
considered as significant.
RESULTS
The affinity of b2m for a2M
The time course of the change in frequency of the
QCM responding to 10 lL of 1 mg/mL a2M was recorded
(Fig. 3A). Association constants (Ka) and the maximum
binding amount (Mmax) were calculated form Eadie-
Hofstee plots (Ka 443.27 nmol/L, Mmax 232.93 Hz)
(Fig. 3B).
b2m exhibited a very strong affinity for a2M in a dose-
dependent manner (Ka 443.27 nmol/L, Fmax 232.93 Hz).
The frequency of the QCM responding to a2M decreased
over time, which indicated that a2M had significant affin-
ity for b2m in a dose-dependent manner.
Serum levels of a2M
Serum levels of a2M were 151.5 ± 43.9 mg/dL in
hemodialysis patients and 157.8 ± 50.3 mg/dL in prehe-
modialysis CRF patients. An increased level of serum
a2M greater than maximum reference value (200 mg/dL
for males and 250 mg/dL for females) could be found only
14 out of 137 cases (10.2%). Serum a2M values in the
hemodialysis patients failed to correlate neither with the
serum b2m values or with the a2M-b2m complex (Fig. 4).
Serum b2m values showed also no correlation with the
a2M-b2m complex (data not shown).
Serum levels of a2M-b2m complex
Serum levels of a2M-b2m complex could not be de-
tected in serum from 15 normal persons, but could be
detected in two out of 11 serums from the prehemodial-
ysis CRF patients (18%), whose levels varied from 0 to
0.8 U/mL (0.09 ± 0.20 U/mL) (Fig. 5). In the hemodial-
ysis patients, the complex could be detected in 95 out of
137 serums (69.3%), which varied from 0 to 1.0 U/mL
(0.20 ± 0.24 U/mL). The complex level in the hemodial-
ysis patients was significantly higher than that in the
prehemodialysis CRF patients (P = 0.013).
Correlation between the serum a2M-b2m complex levels
and clinical characteristics related to hemodialysis
Serum levels of a2M-b2m complex showed a correla-
tion with the duration of hemodialysis (q = 0.257, P =
0.043) (Fig. 6) and an average value of the complex was
significantly higher in the patients with long-term history
of 12 years or more (N = 57) (0.28 ± 0.28 U/mL, 0 to
1.0 U/mL) than that in the patients with a hemodialysis
history less than 12 years (N = 80) (0.15 ± 0.19 U/mL, 0
to 0.9 U/mL) (P = 0.009) (Fig. 7).
Furthermore, no correlation could be found between
serum levels of a2M-b2m complex with the DRA scores
in all hemodialysis patients, but serum complex levels
were significantly higher in patients with high DRA score
than that in patients with negative DRA scores (0.33 ±
0.32 U/mL vs. 0.16 ± 0.21 U/mL, P = 0.018) (Fig. 8).
Even so, however, the time on hemodialysis was also sig-
nificantly longer in the former than in the later, 218.7
months vs. 81.3 months (P < 0.0001).
Serum complex levels in patients who underwent an
operation of carpel tunnel syndrome were 0.32 ± 0.32
U/mL, which was slightly, but not significantly, higher
than 0.19 ± 0.22 U/mL in patients who had not under-
gone an operation (P = 0.065) (data not shown).
An effect of hemodiafiltration on serum levels of
the a2M-b2m complex
Serum levels of the a2M-b2m complex in 11 patients
who had undergone hemodiafiltration for more than
6 months with the high-performance membrane
(hemodiafiltration group) was compared with 34 pa-
tients who had no history of hemodiafiltration with the
high-performance membrane (nonhemodiafiltration
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Fig. 4. Correlation between serum a2-macroglobulin (a2M) and b2-microglobulin (b2m) (A) and a2M-b2m complex (B) in hemodialysis patients.
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Fig. 5. Comparative study of serum levels of
a2-macroglobulin (a2M)-b2-microglobulin
(b2m) complex in the nonhemodialysis
patients with chronic renal failure (CRF)
(prehemodialysis CRF) (N = 11) and the
hemodialysis (HD) patients (N = 137). In
the hemodialysis patients, serum level of
a2M-b2m complex was significantly higher
than the prehemodialysis CRF patients
(control subjects) (0.20 ± 0.24 U/mL vs.
0.09 ± 0.20 U/mL, P = 0.013).
group). In the nonhemodiafiltration group, the duration
of hemodialysis was matched with the hemodiafiltration
group. Duration of hemodialysis was 203.8 ± 51.6
months in the hemodiafiltration group and 205.1 ± 32.8
months in the nonhemodiafiltration group (P = 0.920).
Age was 54.5 ± 6.6 years in the hemodiafiltration group
and 54.4 ± 8.7 years in the nonhemodiafiltration group,
respectively (P = 0.955). Serum values of b2m were
32.8 ± 7.7 mg/L in the hemodiafiltration group and
35.4 ± 6.1 mg/L in the nonhemodiafiltration group (P =
0.252) and serum levels of a2M were 156.0 ± 59.4 mg/dL
in the hemodiafiltration group and 152.2 ± 36.4 mg/dL
in the nonhemodiafiltration group (P = 0.818). Serum
values of a2M-b2m complex were from 0 to 0.3 U/mL
(0.05 ± 0.09 U/mL) in the hemodiafiltration group,
which were significantly lower than not only those in
the nonhemodiafiltration group (from 0 to 1.0 U/mL,
0.31 ± 0.29 U/mL) (P = 0.002) (Fig. 9), but also those in
all hemodialysis patients included in this study (0.20 ±
0.24 U/mL) (P = 0.009). Taking into account this
significant lower value of serum complex in the hemodi-
afiltration patients, a correlation between serum complex
levels and DRA score was further studied in a patient
subgroup excluding 11 hemodiafiltration patients, which
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(b2m) complex in the patient with long term
history of hemodialysis (HD) with more than
12 years (12 years) (N = 57) and counter
hemodialysis patients (<12 years) (N =
87). In the patient with long-term history of
hemodialysi, serum a2M-b2m complex levels
were higher than the counter patient group
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(P = 0.009).
showed a significant correlation as shown in Figure 10
(q = 0.316, P = 0.0004).
DISCUSSION
The presence of a2M in amyloid tissue from patients
with DRA was first demonstrated by Argile´s et al in
1989 [3] and later corroborated by Campistol et al [4].
Thereafter, the complex formation of b2m with a2M was
confirmed directly in an in vitro setting [9] and the a2M
hypothesis for the pathogenesis of DRA was proposed
[10]. Thus far, however, no report concerning a circu-
lating complex of a2M-b2m in hemodialysis patients has
been published.
At present study, we could confirm that a2M showed
high affinity for b2m in vitro by QCM analysis, a new
method for binding assay [13, 14] and detected b2m as-
sociated with a2M (a2M-b2m complex) in serum from
95 out of 137 hemodialysis patients (69.3%). Circulating
levels of a2M were reported to be significantly increased
and had a correlation with the serum levels of b2m in
hemodialysis patients [15, 16]. Interestingly, a significant
correlation between serum levels of a2M and b2m was,
however, limited to the patients with DRA in the study
by Argiles et al [16]. By contrast to that study by Argile´s
et al, this study failed to show such correlation despite
almost similar patient’s background such as duration of
hemodialysis. Two distinct differences could be pointed
out between these two studies, one with serum levels of
a2M and another with proportion of patients with DRA.
Our study involved apparently fewer patients with in-
crease of serum a2M as well as with DRA than the study
of Argile´s et al [16]. Not only was there no increase of
serum a2M but also no correlation between serum levels
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b2-microglobulin (b2m) complex in the
hemodialysis (HD) group (N = 34) and
treated the hemodiafiltration (HDF) group
(N = 11). Serum level of the a2M-b2m
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0.09 U/mL vs. 0.31 ± 0.29 U/mL, P = 0.002).
of a2M and b2m in patients free of DRA in their study
similar to our study. On the other hand, Curatola et al
[15] reported merely a significant increase of serum a2M
in hemodialysis patients. Recently, polymorphism of a2M
gene was reported [17], but to what extent it might be ac-
countable for the difference in serum levels of a2M on
hemodialysis remains unclear.
It is generally acknowledged that b2m is the key sub-
stance in DRA and that the development of DRA is
strongly dependent on the length of time on hemodial-
ysis, which is about 15 years on average in Japan [18].
In our study, a significant correlation was confirmed
between the serum a2M-b2m complex levels and the du-
ration of hemodialysis. However, we failed to find a cor-
relation between the serum value of the a2M-b2m com-
plex and the DRA score. In addition, patients involved in
this study were extremely overbalanced by so many pa-
tients with a negative DRA score, the lower value of the
serum a2M-b2m complex in the hemodiafiltration group
(Fig. 9), which involved more patients with high DRA
scores than in the hemodialysis group and may contribute
to some extent to the lack of correlation with the DRA
score. Actually, a significant correlation with DRA score
and a2M-b2m complex could be confirmed in patient sub-
group excluding hemodiafiltration patients (P = 0.0004)
(Fig. 10).
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Fig. 10. Correlation between serum a2-mac-
roglobulin (a2M)-b2-microglobulin (b2m)
complex in hemodialysis patient subgroup
excluding hemodiafiltration patients and
dialysis-related amyloidosis (DRA) score.
Spearman’s correlation q = 0.316, P = 0.0004.
Although any direct inhibitory effect on protease by
a2M must still be substantiated in DRA amyloid tissue
[19], Argile´s et al [10] have given a clear indications that
the a2M-b2m complex has great pathophysiologic signifi-
cance in DRA and stressed the importance of an impaired
catabolism of extravasated b2m in amyloid tissue by pro-
tection from protease [10].
A kinetic study of b2m using 125I-b2m suggested a pro-
gressive accumulation of b2m in the extravascular space
along with the time on hemodialysis [20, 21], while the
serum b2m concentrations tended to level off [22].
Because the bounding of the a2M-b2m complex was
reported to be extremely tight, as indicated by an
estimated kD of 10−9 mol/L [10], which was almost
similar value in this study, a preformed complex is, there-
fore, assumed unlikely to be dissociated in the physiologic
condition.
A molecular size of the complex is unlikely to be
removed even by hemodiafiltration. Under such circum-
stance, circulating levels of the complex might be depen-
dent on the extent by which the complex is generated.
Thus, it makes sense to assume that a lower value of
serum complex in the hemodiafiltration group compared
with the nonhemodiafiltration group may be due to lower
b2m value in those patients, albeit not significant, by high
shuttling effect across the vascular wall of convection
flow.
A recent report by Narita et al [23] suggested the pos-
sibility of a different process from the one involving the
protection from protease, which is mediated via a low-
density lipoprotein receptor-related protein (LRP). They
have shown that the amyloid b peptide-a2M complex is
degraded by glioblastoma cells and fibroblast via LRP.
Although it is not clear to what extent this process con-
tributes to a2M-b2m catabolism, it is well-known that the
involvement of activated macrophages would be ubiqui-
tous in the late stages of DRA [24–26]. a2M is also re-
ported to bind to LRP on macrophages. Accordingly, an
analogous possibility could be suggested in catabolism of
a2M-b2m complex.
As shown in a statement by Glabe [27] concerning the
up-to-date report by Iwata et al [28], the overall evidence
from an investigation on the catabolic breakdown of amy-
loid proteins can be anticipated to provide new insights
into the pathogenesis of the amyloidosis.
Of greater interest, the binding site of b2m to a2M
was reported to be folded in the physiologic state [9].
The complex, therefore, may indicate the presence of an
unfolded b2m, which suggests a conformational change
in this molecule, misfolding, in vivo [29].
Finally, as stated in a paragraph compared with the
study by Argile´s et al, this study involved many patients
free of clinical evidences of DRA, which might enable us
to undertake further study on prognostic value of a2M-
b2m complex in progression of DRA.
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